PUBLISHER: The Business Research Company | PRODUCT CODE: 1942552
PUBLISHER: The Business Research Company | PRODUCT CODE: 1942552
Cervical cancer is a form of squamous cell carcinoma that develops in the cervix, which is the lower part of the uterus. Diagnostic devices for cervical cancer are employed to detect cancer affecting the cervix.
The primary types of cervical cancer diagnostics include pap smear tests, HPV tests, colposcopy, biopsy, endocervical curettage, and other diagnostic procedures. A pap smear test is a method used for the detection of cervical cancer in women. This diagnostic process encompasses age groups such as those under 21, those aged 21 to 29, those aged 30 to 65, and those over 65. These diagnostics are utilized by various end-users, including hospitals, specialty clinics, cancer and radiation therapy centers, as well as diagnostic centers.
Tariffs are influencing the cervical cancer diagnostics market by increasing costs of imported diagnostic instruments, reagents, imaging systems, optical components, and laboratory equipment. Diagnostic centers and hospitals in North America and Europe are most affected due to reliance on imported diagnostic platforms, while Asia-Pacific faces cost pressures on test kit production and equipment sourcing. These tariffs are increasing testing costs and slowing equipment upgrades. However, they are also encouraging domestic diagnostic manufacturing, local reagent production, and expansion of regional diagnostic capabilities.
The cervical cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides cervical cancer diagnostics market statistics, including cervical cancer diagnostics industry global market size, regional shares, competitors with a cervical cancer diagnostics market share, detailed cervical cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the cervical cancer diagnostics industry. This cervical cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The cervical cancer diagnostics market size has grown strongly in recent years. It will grow from $9.76 billion in 2025 to $10.37 billion in 2026 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to expansion of cervical cancer screening programs, increased awareness of women's health, availability of pap smear testing technologies, growth in diagnostic laboratory networks, rising incidence of cervical cancer.
The cervical cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $12.89 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to increasing adoption of molecular diagnostic tests, rising investments in cancer prevention programs, expansion of digital pathology adoption, growing focus on early-stage cancer diagnosis, continuous innovation in diagnostic technologies. Major trends in the forecast period include increasing adoption of hpv-based screening programs, rising use of digital and optical colposcopy systems, growing integration of ai-assisted diagnostic tools, expansion of population-based screening initiatives, enhanced focus on early cancer detection.
The increasing prevalence of cervical cancer is expected to drive growth in the cervical cancer diagnostics market in the coming years. Cervical cancer originates in the cells of the cervix, the narrow, lower portion of the uterus that connects to the top of the vagina. Cervical cancer diagnostics are critical for early detection, accurate diagnosis, and effective treatment. For instance, in February 2023, according to Cancer.net, the patient information website of the American Society of Clinical Oncology (ASCO), an estimated 13,960 women in the United States were diagnosed with invasive cervical cancer. Therefore, the rising prevalence of cervical cancer is expected to fuel the cervical cancer diagnostics market.
Leading companies in the cervical cancer diagnostics market are focusing on developing technologically advanced solutions, such as digital diagnostic systems, to improve accessibility to screening and enhance early detection. A digital diagnostic system for cervical cancer uses artificial intelligence (AI) and digital tools to support detection, diagnosis, and management of the disease. For example, in February 2024, Hologic, Inc., a U.S.-based health technology company, received FDA clearance for its Genius Digital Diagnostics System, which incorporates the Genius Cervical AI algorithm for cervical cancer screening. This system is the first to combine deep-learning AI with advanced volumetric imaging technology, significantly improving the detection of pre-cancerous lesions and cervical cancer cells. It reduces false negatives by 28% compared to traditional methods, enhancing early diagnosis and patient outcomes. The system digitizes cytology slides and uses AI to assist cytologists and pathologists in identifying areas requiring further review, streamlining workflows and enabling remote collaboration among healthcare professionals.
In March 2024, Halma plc, a UK-based life-saving technology company, acquired Rovers Medical Devices B.V. for an undisclosed amount. The acquisition strengthens Halma's healthcare portfolio by integrating Rovers' cervical cancer screening technologies, including its widely used Cervex-Brush sample-collection device. It further enhances Halma's position in women's health diagnostics by expanding its offerings in cervical cancer prevention and screening consumables across international markets. Rovers Medical Devices B.V. is a Netherlands-based company that designs and manufactures cervical sample-collection devices for cancer diagnostics.
Major companies operating in the cervical cancer diagnostics market are Abbott Laboratories, Becton Dickinson and Company, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Hologic Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Siemens Healthineers AG, Zilico Ltd., Guided Therapeutics Inc., Thermo Fisher Scientific Inc., Carl Zeiss AG, Arbor Vita Corporation, Micromedic Technologies Ltd., Roche Diagnostics, Nucleix Ltd., BGI Genomics Co. Ltd., Cepheid, Exact Sciences Corporation, Invitae Corporation, NeoGenomics Laboratories Inc., PerkinElmer Inc., Sysmex Corporation, Veracyte Inc., Zymo Research Corporation
North America was the largest region in the cervical cancer diagnostics market in 2025. Asia-Pacific was the second largest region in the cervical cancer diagnostics market. The regions covered in the cervical cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the cervical cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The cervical cancer diagnostics market consists of sales of analyzer, reagents, and others that are used for the diagnosis of cervical cancer. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Cervical Cancer Diagnostics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses cervical cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for cervical cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cervical cancer diagnostics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.